The search for effective treatments for chronic fatigue remains one of the most challenging areas in medicine. Recent findings highlighted in an article about the future of interventional psychiatry suggest that ketamine may offer a new avenue for addressing severe, persistent fatigue that has resisted conventional approaches. For patients living with debilitating exhaustion, even modest improvements could have meaningful effects on quality of life.
Chronic Fatigue Remains Difficult To Treat
Chronic fatigue affects millions of people worldwide and is commonly associated with conditions such as cancer survivorship, fibromyalgia, systemic lupus erythematosus, and myalgic encephalomyelitis/chronic fatigue syndrome. Unlike ordinary tiredness, chronic fatigue often persists despite rest and can significantly impair daily functioning.
Current treatment options are limited. Many interventions focus on managing underlying medical conditions rather than directly targeting fatigue itself. As a result, researchers continue searching for therapies capable of rapidly reducing symptoms while improving overall functioning.
Why Researchers Explored Ketamine For Chronic Fatigue
Ketamine has gained significant attention in psychiatry because of its rapid antidepressant effects. Researchers have also become interested in its ability to influence inflammatory pathways and glutamate signaling within the nervous system.
Previous investigations suggested that fatigue may be linked to excessive activation of certain immune and nervous system pathways. Because ketamine blocks specific glutamate receptors and may reduce inflammatory activity, scientists hypothesized that it could interrupt biological processes contributing to persistent exhaustion.
To explore this possibility, investigators conducted a preliminary proof-of-concept trial involving adults with severe chronic fatigue arising from different medical conditions.
A Small But Carefully Designed Clinical Trial
The study enrolled ten adults experiencing significant fatigue for at least six months during the previous year. Participants included cancer survivors as well as individuals diagnosed with fibromyalgia, lupus, and myalgic encephalomyelitis/chronic fatigue syndrome.
Researchers used a randomized, double-blind crossover design. Participants received either a low-dose intravenous ketamine infusion or midazolam, a sedative commonly used as a comparison treatment in ketamine studies. After a two-week washout period, participants received the alternate treatment.
Fatigue levels were measured repeatedly during the week following each infusion, allowing investigators to track short-term symptom changes.
Ketamine For Chronic Fatigue Produced Rapid Improvements
The most encouraging findings emerged during the first phase of the study. Participants who received ketamine experienced a 21% reduction in fatigue scores by the third day after treatment. The greatest improvement occurred one day after infusion, when fatigue scores dropped by nearly 39%.
Although participants receiving midazolam also reported symptom improvement, ketamine successfully exceeded the researchers’ predefined benchmark of a 20% reduction in fatigue symptoms.
These findings suggest that ketamine may have rapid anti-fatigue effects similar to the fast symptom relief observed in depression treatment studies.
Understanding The Biological Mechanisms
One reason these findings are particularly interesting is the growing evidence connecting inflammation, immune signaling, and nervous system dysfunction to chronic fatigue.
Researchers believe ketamine may influence multiple biological systems simultaneously. By blocking N-methyl-D-aspartate receptors and altering glutamate activity, ketamine may reduce excessive neural signaling associated with fatigue. It may also affect inflammatory pathways that contribute to feelings of exhaustion across various chronic illnesses.
This dual mechanism could help explain why researchers continue exploring ketamine’s therapeutic potential beyond depression.
Important Limitations Temper Enthusiasm
Despite the promising signals, the study has important limitations.
The sample size was extremely small, with only ten participants completing the trial. Researchers originally intended to enroll nearly sixty individuals, but recruitment challenges significantly reduced participation.
In addition, the crossover design created unexpected complications. Participants entered the second treatment phase with lower fatigue levels than expected, suggesting lingering effects from the initial intervention. Midazolam may also have provided fatigue relief of its own, making it more difficult to detect differences between treatments.
Because of these factors, the results should be viewed as preliminary rather than definitive.
What This Means For Interventional Psychiatry
While larger studies are necessary, this research highlights an emerging opportunity within interventional psychiatry. Fatigue remains a major unmet clinical need across multiple medical conditions, and few therapies produce rapid symptom improvement.
Future trials with larger patient populations, alternative control treatments, and improved study designs may help clarify whether ketamine can become a meaningful treatment option for chronic fatigue. For now, the findings provide an intriguing early signal that deserves further scientific investigation.
As researchers continue exploring innovative applications of ketamine, studies like this expand our understanding of how interventional treatments might address symptoms that extend beyond traditional psychiatric disorders.
Citations
Goto T, Kreskow JD, Ross ALR, Blumhorst CL, Zhao JJ, Mannes AJ, Bačkonja M, Zarate CA Jr, Saligan LN. A preliminary proof-of-concept trial on the effects of ketamine on fatigue: a randomized crossover trial. Pharmacological Reports. 2026. PMID: 41569403. Available at: https://pubmed.ncbi.nlm.nih.gov/41569403/
Petrova K. Low-dose ketamine shows promise for easing chronic fatigue. PsyPost, May 24, 2026. Available at: https://www.psypost.org/low-dose-ketamine-shows-promise-for-easing-chronic-fatigue/
Explore more at https://www.interventionalpsychiatry.org/